The potential of angiogenesis soluble markers in chronic hepatitis C

Authors

  • Xamila Salcedo,

    1. Liver and Molecular Biology Units, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Spain
    Search for more papers by this author
    • Xamila Salcedo and Jesús Medina contributed equally to this work.

  • Jesús Medina,

    1. Liver and Molecular Biology Units, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Spain
    Search for more papers by this author
    • Xamila Salcedo and Jesús Medina contributed equally to this work.

  • Paloma Sanz-Cameno,

    1. Liver and Molecular Biology Units, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Spain
    Search for more papers by this author
  • Luisa García-Buey,

    1. Liver and Molecular Biology Units, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Spain
    Search for more papers by this author
  • Samuel Martín-Vilchez,

    1. Liver and Molecular Biology Units, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Spain
    Search for more papers by this author
  • María J. Borque,

    1. Liver and Molecular Biology Units, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Spain
    Search for more papers by this author
  • Manuel López-Cabrera,

    1. Liver and Molecular Biology Units, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Spain
    Search for more papers by this author
  • Ricardo Moreno-Otero

    Corresponding author
    1. Liver and Molecular Biology Units, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Spain
    • Unidad de Hepatología (planta 3), Hospital Universitario de la Princesa, Diego de León 62, E-28006-Madrid, Spain
    Search for more papers by this author
    • fax: (34) 9-14022299


  • Conflict of interest: Nothing to report.

Abstract

Angiogenesis, the formation of new vessels, has been reported to play a significant pathogenic role in liver damage–associated hepatitis C virus infection. Most of our current knowledge derives from immunohistochemical studies of hepatic biopsy samples obtained from chronic hepatitis C (CHC) patients. We evaluated whether CHC is associated with elevated serum levels of angiogenesis markers and whether these are modulated by therapy. Vascular endothelial growth factor (VEGF), angiopoietin-2 (Ang-2), and soluble Tie-2 (sTie-2) were determined in the serum of 36 CHC patients, before and after receiving antiviral combination therapy with pegylated interferon alpha-2b plus ribavirin, and in 15 healthy controls. CHC patients showed elevated baseline VEGF and Ang-2 levels. After treatment, both factors were decreased, whereas antiangiogenic sTie-2 was increased, indicating a shift toward an “anti-angiogenic” profile of serum markers in CHC patients. In conclusion, this suggests that serum VEGF, Ang-2, and sTie-2 levels could be useful as noninvasive, mechanistically based markers of response to therapy and disease progression in CHC. (HEPATOLOGY 2005.)

Ancillary